Exon skipping is capable of correcting frame-shift and nonsense mutations of
Duchenne Muscular Dystrophy (DMD). Phase II clinical trials in UK and Netherlands
have reported induction of dystrophin expression in muscles of DMD patients by
systemic administrations of both phosphorodiamidate morpholino oligomers (PMO)
and 2’O methyl phosphorothioate. Peptide-conjugated PMO (PPMO)...